Sam Penza
Overview
Explore the profile of Sam Penza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
375
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang J, Sigmund A, Zhao Q, Elder P, Vasu S, Jaglowski S, et al.
Leuk Lymphoma
. 2024 Jun;
65(11):1698-1705.
PMID: 38865104
Chronic graft--host-disease (cGVHD) is one of the primary causes of morbidity and mortality for patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HCT). In recent years, advancements in allo-HCT have...
2.
Faisal M, Hanel W, Voorhees T, Li R, Huang Y, Khan A, et al.
Cancer Med
. 2023 Jan;
12(7):8228-8237.
PMID: 36653918
Background: Relapsed or refractory Hodgkin lymphoma (R/R HL) is a challenging disease with limited treatment options beyond brentuximab vedotin and checkpoint inhibitors. Herein we present the time-trend analysis of R/R...
3.
Jiang J, Sigmund A, Zhao Q, Elder P, Benson D, Vasu S, et al.
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428678
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative treatment for many hematological disorders, but is often complicated by relapse of the underlying disease, graft-versus-host disease (GVHD), and infectious...
4.
Sigmund A, Zhao Q, Jiang J, Elder P, Benson D, Rosko A, et al.
Front Oncol
. 2022 Mar;
12:801879.
PMID: 35280722
Background: Allogeneic hematopoietic stem cell transplant (allo-HCT) is a potential curative therapy for a variety of hematologic disorders. However, it requires highly specialized care that is only available at select...
5.
Sigmund A, Denlinger N, Huang Y, Bond D, Voorhees T, Bajwa A, et al.
Transplant Cell Ther
. 2022 Mar;
28(6):342.e1-342.e5.
PMID: 35248778
Anti-CD19 chimeric antigen receptor T cell therapy (CAR19) represents a critical treatment modality for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, the majority of patients subsequently experience...
6.
Bajwa A, Huang Y, Li R, Denlinger N, Brammer J, Penza S, et al.
Leuk Lymphoma
. 2022 Feb;
63(6):1492-1495.
PMID: 35109749
No abstract available.
7.
Vasu S, Bostic M, Zhao Q, Sharma N, Puto M, Knight S, et al.
Blood Adv
. 2021 Dec;
6(4):1342-1349.
PMID: 34932790
Hematopoietic cell transplantation-associated thrombotic microangiopathy (TMA) is a complication associated with higher nonrelapse mortality (NRM) in patients who undergo allogeneic transplant (HCT). Current classification criteria are not generally agreed on...
8.
Schaefer A, Huang Y, Kittai A, Maakaron J, Saygin C, Brammer J, et al.
Cancer Manag Res
. 2021 Dec;
13:8901-8906.
PMID: 34876852
Introduction: Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Treatment with CD19 chimeric antigen receptor (CAR-T) cells, tisagenlecleucel and axicabtagene ciloleucel, has been associated with improved outcomes....
9.
Brammer J, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, et al.
J Immunother Cancer
. 2021 Aug;
9(8).
PMID: 34429331
Background: Chimeric antigen receptor T-cell (CAR-T) infusion is associated with early toxicity. Yet, whether early toxicity development holds ramifications for long-term outcomes is unknown. Methods: From a large cohort of...
10.
Sharma N, Faisal M, Zhao Q, Jiang J, Elder P, Benson D, et al.
J Clin Med
. 2021 Jul;
10(13).
PMID: 34199028
Allogeneic hematopoietic cell transplantation (allo-HCT) from a haploidentical (haplo) donor has emerged as a suitable alternative in the absence of a matched donor. However, haplo-HCT patients have a higher risk...